Amarin Corporation plc AMRN announced today that the US PTO has published notification of Notice of Allowance for
U.S. Patent Application Serial Number 13/608,775. This application includes
claims intended to protect the Vascepa^® (icosapent ethyl) indication approved
in July 2012 by the U.S. Food and Drug Administration (FDA) based on Amarin's
MARINE clinical trial results. This application is a continuation of Amarin's
U.S. Patent Number 8,293,728 (formerly, the '153 application) and broadens the
'728 claims by covering the use of Vascepa with and without other lipid
lowering agents, such as statins. The '775 application claims gauge drug
effects against placebo control.
A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. After issuance, Amarin plans to list
this patent in the FDA's Approved Drug Products with Therapeutic Equivalence
Evaluations, or Orange Book.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in